Panic Disorder
Conditions
Brief summary
The objectives of this survey was to retrospectively collect and evaluate the information on the efficacy and safety of PAXIL tablets (PAXIL, hereinafter) in pediatric subjects (aged under 18) with panic disorder under conditions of actual use.
Interventions
DRUGParoxetine
Sponsors
GlaxoSmithKline
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 17 Years
Inclusion criteria
* Aged under 18 at the time of the panic disorder diagnosis * Aged under 18 on the starting day of PAXIL treatment * Having been making periodic visits to the hospital to receive treatment for panic disorder
Exclusion criteria
* Subjects who have been treated with paroxetine prior to this investigation * Subjects with hypersensitivity to paroxetine * Subjects taking monoamine oxidase inhibitors (MAOIs) or within 2 weeks of stopping treatment with MAOIs * Concomitant use in patients taking pimozide
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events in Japanese pediatric subjects with panic disorder treated with paroxetine tablet based on prescribing information under the conditions of general clinical practice | From the starting day of the treatment to the time of treatment termination/discontinuation was assessed from 1 month at minimum up to 2 years |
| Efficacy evaluation based on overall improvement | From the starting day of the treatment to the time of treatment termination/discontinuation was assessed from 1 month at minimum up to 2 years |
Outcome results
None listed